Table 2.
Kallikrein activity and kinin peptides measured in bronchoalveolar lavage fluid.
| Control | COVID-19 | p-value | |
|---|---|---|---|
| Lys-bradykinin (pg/mL) | 7·1 [0·0-120·0] | 7·3 [0·0-152·0] | 0·751 |
| Lys-bradykinin-(1-8) (pg/mL) | 5·3 [0·0-72·6] | 5·3 [0·0-108·0] | 0·415 |
| Bradykinin (pg/mL) | 14·3 [0·0-459·0] | 12·7 [0·0-261·0] | 0·432 |
| Bradykinin-(1-8) (pg/mL) | 0·0 [0·0-867·0] | 17·7 [0·0-700·0] | 0·062 |
| Bradykinin-(1-7) (pg/mL) | 28·4 [3·3-460·0] | 97·2 [0·0-3583·0] | 0·056 |
| Bradykinin-(1-5) (pg/mL) | 0·0 [0·0-374·0] | 89·6 [0·0-2425·0] | 0·001 |
| Total hydrolytic activity (eq. PKal, pM) | 14·4 [2·4-52·0] | 41·9 [7·8-1574·0] | 0·037 |
| Plasma kallikrein activity (pM) | 0·3 [0·0-2·4] | 2·1 [0·0-41·7] | 0·173 |
| Tissue kallikrein activity (pM) | 3·8 [0·0-22·0] | 18·2 [1·2-1535·0] | 0·030 |
Results are reported as medians with [min – max range]. Kinin peptides measurements are available for 21 patients with COVID-19 and 19 control patients (characteristics shown in Table 1). Kallikrein activity measurements are available for 9 patients with COVID-19 and 11 control patients.